NEW YORK (TheStreet) -- Drug company Bristol Myers Squibb reported third-quarter earnings of 61 cents a share, above the average analyst estimate of 58 cents. The company also revised its full-year guidance to $2.25 to $2.30 a share from $2.20 to $2.30 a share. The earnings release comes on the heels of Bristol-Myers Squibb's announcement that it will develop a once-a-day pill to treat HIV patients by combining its Reyataz treatment with an experimental drug from Gilead Sciences.
Comment on 8 Stocks to Watch: Bristol-Myers, Altria
twocents@thestreet.com (Andrea Tse), The Street
Thu, 10/27/2011 - 5:15am
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more